Gut-liver axis: Pathophysiological concepts and clinical implications
H Tilg, TE Adolph, M Trauner - Cell metabolism, 2022 - cell.com
Bidirectional crosstalk along the gut-liver axis controls gastrointestinal health and disease
and exploits environmental and host mediators. Nutrients, microbial antigens, metabolites …
and exploits environmental and host mediators. Nutrients, microbial antigens, metabolites …
[HTML][HTML] Immune cell-mediated features of non-alcoholic steatohepatitis
T Huby, EL Gautier - Nature reviews immunology, 2022 - nature.com
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
[HTML][HTML] Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Previous studies have suggested that the gut microbiome influences the response to
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
[HTML][HTML] Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives
N Vallianou, GS Christodoulatos, I Karampela… - Biomolecules, 2021 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non …
worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non …
A researcher's guide to preclinical mouse NASH models
Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …
[HTML][HTML] Excess body weight: Novel insights into its roles in obesity comorbidities
Excess body weight is a global health problem due to sedentary lifestyle and unhealthy diet,
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …
[HTML][HTML] Short-chain fatty acids in diseases
D Zhang, YP Jian, YN Zhang, Y Li, LT Gu… - Cell Communication and …, 2023 - Springer
Short-chain fatty acids (SCFAs) are the main metabolites produced by bacterial fermentation
of dietary fibre in the gastrointestinal tract. The absorption of SCFAs is mediated by substrate …
of dietary fibre in the gastrointestinal tract. The absorption of SCFAs is mediated by substrate …
Gut–liver axis: barriers and functional circuits
The gut and the liver are characterized by mutual interactions between both organs, the
microbiome, diet and other environmental factors. The sum of these interactions is …
microbiome, diet and other environmental factors. The sum of these interactions is …
Endoplasmic reticulum stress and lipids in health and diseases
The endoplasmic reticulum (ER) is a complex and dynamic organelle that regulates many
cellular pathways, including protein synthesis, protein quality control, and lipid synthesis …
cellular pathways, including protein synthesis, protein quality control, and lipid synthesis …
Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis
Y Rao, Z Kuang, C Li, S Guo, Y Xu, D Zhao, Y Hu… - Gut …, 2021 - Taylor & Francis
The gut bacterium Akkermansia muciniphila has been increasingly recognized for its
therapeutic potential in treating metabolic disorders, including obesity, diabetes, and …
therapeutic potential in treating metabolic disorders, including obesity, diabetes, and …